Pure Life Healthcare Management

Pure Life Healthcare Management: Full-spectrum Strategy for PTSD Care


Pure Life Healthcare Management aims to change the healthcare landscape for people suffering from post-traumatic stress disorder (PTSD) with more than 20 services to support PTSD and trauma, creating a wrap-around healthcare ecosystem that provides patients with everything they need to heal.

The company is backed by an experienced team with a deep understanding of issues surrounding mental health. It is also structured to leverage its own value chain, which includes wrap-around care clinics, occupational therapy, alternative medical treatments, pharmacies and partnerships with organizations such as Heroes Haven Society.

Purelife Key Services and Partnerships ​Key Services and Partnerships

Pure Life Healthcare Management’s wraparound approach to healthcare will provide support throughout the entire healing process, from counseling and medical testing to dentistry and physiotherapy. The majority of clients are expected to require only a light to medium touch, with one to six visits per month. However, Pure Life also expects a minority of highly complex cases which will require up to $100,000 annually per client with 10 to 20 visits per month.

Company Highlights

  • Over 1.3 million Canadians currently struggle with PTSD and trauma, a population largely underserved by the country's mental health services.
  • Canada is implementing a National Strategy for PTSD focused on prevention, early treatment and intervention, increasing funding for mental health services and looking for partners.
  • Pure Life Healthcare Management is strategically positioned to be among these partners.
  • Pure Life Healthcare Management offers more than 20 services to support PTSD and trauma, creating a wrap-around healthcare ecosystem that provides patients with everything they need to heal.
  • The company is backed by an experienced leadership team and a business structure designed to maximize the value chain, which includes:
    • Wrap-around care clinics
    • Pharmacies
    • Alternative medicines
    • Occupational therapies
    • Partnerships
    • Joint ventures
    • Real estate and commercial holdings
  • One of Pure Life Healthcare Management's most prominent partnerships is with the non-profit Heroes Haven Society, which provides free testing and support for individuals suffering from trauma.
  • The majority of Pure Life Healthcare Management’s revenue will stem from government and insurance benefits.
  • Pure Life Healthcare Management has begun with a virtual model, and is preparing to acquire its first physical location in 2023. The virtual presence will be maintained to serve the remote and restricted community, and as a way to measure patient concentration by area, driving physical location demand and profitability from day one. This strategy is expected to deliver the following revenues:
    • Phase 1 (2023): $690,000 with 14,400 clients and one physical location.
    • Phase 2 (2024): $29.90 million with 27,000 clients and two physical locations.
    • Phase 3 (2025): $90.85 million with 40,000 clients and four physical locations.

This Pure Life Healthcare Management profile is part of a paid investor education campaign.*

Click here to connect with Pure Life Healthcare Management to receive an Investor Presentation

Transition Metals

Transition Metals Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Transition Metals (TSXV:XTM)

Transition Metals

Mitigating Risk. Multiplying Opportunities Across Canada’s Critical and Precious Metals

Mitigating Risk. Multiplying Opportunities Across Canada’s Critical and Precious Metals Keep Reading...
Stethoscope rests on stacks of US money over a bright blue background.

Eli Lilly to Buy Psychedelics Firm AtaiBeckley for US$2.8 Billion

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is pushing further into the psychedelic drug market with a US$2.8 billion buyout of clinical-stage developer AtaiBeckley (NASDAQ:ATAI). The crown jewel of the deal is BPL-003, a clinic-administered nasal spray derived from dimethyltryptamine... Keep Reading...
BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer

BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer

Sunnybrook's Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell's pivotal Phase 3 clinical trial in metastatic breast cancerBriaCell Phase 3 trial featured in Nature Medicine as one of "Eleven clinical trials that will shape medicine in 2026" briacell... Keep Reading...
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT

Arrangement with FUJIFILM Biotechnologies California provides manufacturing capacity for the remainder of BriaCell's pivotal Phase 3 study and commercial scalability potential Bria-IMT is currently being evaluated in Bria-Cell's ongoing pivotal Phase 3 study in metastatic breast cancer briacell... Keep Reading...
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT

Charles River Associates (CRA) to evaluate epidemiology, pricing, prescriber dynamics, and market access potential for Bria-IMT in metastatic breast cancer in the USKaleio to support brand strategies and customized commercial-readiness solutionsBria-IMT is currently being evaluated in... Keep Reading...
Syringes with measurement markings overlaid with a fluctuating blue and white line graph.

Zymeworks Expands into Respiratory Market with Theravance Buyout

Oncology-focused drugmaker Zymeworks (NASDAQ:ZYME) has agreed to acquire Theravance Biopharma (NASDAQ:TBPH) for US$929 million in cash, expanding its portfolio into the respiratory segment.The acquisition delivers Zymeworks a 35 percent US net profit share in Yupelri, the first and only... Keep Reading...
Rows of multicolored test tubes with brown, purple, blue and green caps arranged neatly on a white rack.

Merck KGaA to Acquire Bio-Techne in US$11.3 Billion Deal

Merck KGaA (ETR:MRK,OTCPL:MKGAF) has agreed to acquire life sciences supplier Bio-Techne (NASDAQ:TECH) for US$11.3 billion in cash, marking the firm’s largest transaction in a decade.Under a definitive agreement announced on Thursday (June 25), Merck KGaA will pay US$73 per share, representing a... Keep Reading...
Transition Metals

Transition Metals Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Interactive Chart

Latest Press Releases

Related News